ERBB4 Promoter Polymorphism Is Associated with Poor Distant Disease-Free Survival in High-Risk Early Breast Cancer

• Kari J. Kurppa,

  Affiliations Department of Medical Biochemistry and Genetics and Medicity Research Laboratories, University of Turku, Turku, Finland, Turku Doctoral Programme of Molecular Medicine, Turku, Finland

  ⨯
• Matjaz Rokavec,

  Current address: Experimental and Molecular Pathology, Institute of Pathology, Ludwig-Maximilians-University Munich, Munich, Germany

  Affiliations Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany, University of Tübingen, Tübingen, Germany

  ⨯
• Maria Sundvall,

  Current address: Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachussetts, United States of America

  Affiliations Department of Medical Biochemistry and Genetics and Medicity Research Laboratories, University of Turku, Turku, Finland, Department of Oncology, Turku University Hospital, Turku, Finland

  ⨯
• Pirkko-Liisa Kellokumpu-Lehtinen,

  Affiliation Department of Oncology, Tampere University Hospital, Tampere, Finland

  ⨯
• Heikki Joensuu,

  Affiliation Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland

  ⨯
• Hiltrud Brauch,

  Affiliations Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany, University of Tübingen, Tübingen, Germany

  ⨯
• Klaus Elenius

  * E-mail: klaus.elenius@utu.fi

  Affiliations Department of Medical Biochemistry and Genetics and Medicity Research Laboratories, University of Turku, Turku, Finland, Department of Oncology, Turku University Hospital, Turku, Finland

  ⨯